🏛️ Verified NIH Record • Updated 2026-06-12
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (NCT06045689)
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0051 — Los Alamitos, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- Local Institution - 0051 — Los Alamitos, California
- Local Institution - 0033 — New Haven, Connecticut
- Local Institution - 0055 — St. Petersburg, Florida
- Local Institution - 0056 — Wellington, Florida
- Local Institution - 0020 — Kansas City, Kansas
- Local Institution - 0025 — Paducah, Kentucky
- Local Institution - 0011 — Detroit, Michigan
- Local Institution - 0059 — St Louis, Missouri
- Local Institution - 0058 — Morristown, New Jersey
- Local Institution - 0032 — New York, New York
- Local Institution - 0054 — Eugene, Oregon
- Local Institution - 0036 — Pittsburgh, Pennsylvania
- Local Institution - 0043 — Amarillo, Texas
- Local Institution - 0022 — Huntsville, Texas
- Local Institution - 0031 — Wheeling, West Virginia
- Local Institution - 0003 — Milwaukee, Wisconsin
- Local Institution - 0016 — Leuven, Vlaams Brabant
- Local Institution - 0008 — Roeselare, West-Vlaanderen
- Local Institution - 0023 — Prague, Praha, Hlavní Mesto
- Local Institution - 0004 — Prague, Praha, Hlavní Mesto
- Local Institution - 0041 — Nice, Alpes-Maritimes
- Local Institution - 0001 — Poitiers, Vienne
- Local Institution - 0026 — Angers,
- Local Institution - 0007 — Grenoble,
- Local Institution - 0046 — Paris,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndromes
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Lakewood, California
- Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida
Explore by condition: All Myelodysplastic Syndromes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.